Diagnosis and Control of Lymphatic Filariasis with Special Emphasis on Gene Editing Method

05

Safa Azhar[1], Muhammad Abdullah[2], Muhammad Shuaib Shafi[3], Farwa Rizwan[4], Hikmat Ullah[5], Shaukat Ullah[6], Warda Qamar[7], Fakhar Un Nisa[8], Farhad Badshah[9], Calvin R Wei[10] and Muhammad Sohail[11]

ABSTRACT

Lymphatic filariasis stands with a significance global public health concern. In order to proceed for the control and treatment of the disease, the analysis of its diagnosis deserves crucial attention. Likewise other diseases, the diagnostics of lymphatic filariasis includes several physical examinations, molecular assays as well as serological methods of diagnostics. The efforts have been made of achieving milestone in developing drug with specific efficacy. Drug therapy through anti filarial drugs has been a cornerstone in order to control and eliminate LF globally. With pharmaceutical intervention, health professionals attempts to increase effectiveness of these drugs through designing drug combinations. However, it is important to note that prevention is favored to control LF. Disease control through certain drugs is employed by MDA program. It is majorly aiming to target agents for transmission (worms and microfilariae). Complementary strategies to lessen the prevalence of filarial vectors include vector control. Systematic tracking, surveillance, community engagement and strengthening healthcare infrastructure in endemic areas are some collaborative efforts to control the disease.

The limitations of the control strategies such like drug resistance lead to emergence of promising technique i.e gene therapy. The Cas9 CRISPR technology has provided revolutionary treatment in all recent times. The genomes of filarial parasites are being edited and modifications are being made. This will create hindrance in transmission cycle, reproduction cycle of parasites and worms. In the result, parasite become inactive and is destructed. The gene therapy delivered by viral vectors, nano particles or any other molecular vehicles. However, the Cas9 system is known for its precision, versatility and transformative effects. Still there is intervention of regulatory, ethical considerations and not this technique is able to be delivered to all targeted population of world. The Genome editing has the potential to transform the strategies for disease management. It can revolutionize the lymphatic filariasis control and prevention agenda. The comprehensive identity of genome editing if used in union of existing techniques, can execute sustained disease elimination.

CITATION

Azhar S, Abdullah M, Shafi MS, Rizwan F, Ullah H, Ullah S, Qamar W, Nisa F, Badshah F and Wei C, Muhammad Sohail11, 2023. Diagnosis and Control of Lymphatic Filariasis with Special Emphasis on Gene Editing Method. In: Abbas RZ, Hassan MF, Khan A and Mohsin M (eds), Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan, Vol 2: 58-72. https://doi.org/10.47278/book.zoon/2023.52

CHAPTER HISTORY Received: 27-Feb-2023 Revised: 22-April-2023 Accepted: 12-Aug-2023

[1]Department of Biotechnology, University of Central Punjab, Lahore, Pakistan

[2]Department of Biochemistry, University of Central Punjab, Lahore, Pakistan
[3]University College of Veterinary Science, The Islamia University of Bahawalpur, Pakistan
[4]Department of Anatomy and Histology, University of Veterinary and Animal Sciences, Lahore
[5]Department of Microbiology, Kohat University of Science and Technology Kohat, Pakistan
[6]Department of Zoology, University of Peshawar kpk, Pakistan
[7]Department of Parasitology, University of Agriculture Faisalabad, Pakistan
[8]Department of Animal Breeding and Genetics, Faculty of Animal Production and Technology, Ravi Campus, UVAS, Pakistan
[9]State Key Laboratory of Animal Biotech Breeding, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China
[10]Department of Research and Development, Shing Huei Group, Taipei, Taiwan
[11]Department of Pathology, Faculty of Veterinary Sciences, University of Agriculture Faisalabad Pakistan
***Corresponding author:** ras131974@gmail.com

1. INTRODUCTION

Elephantiasis, also known as lymphatic filariasis, is a parasitic condition brought on by Wuchereria bancrofti, Brugia malayi, and Brugia timori, three species of thread-like worms (nematodes) known as filarial worms. It is mainly spread to people via mosquito bites that are contaminated. The illness is a serious public health hazard and is common in tropical and subtropical areas of the world (Chandrasena et al. 2018; Lourens and Ferrell 2019). This disease can be deadly but early diagnosis can be the smart strategy towards the management of the disease. This includes the detection of microfilariae in the blood of humans which is transmitted through mosquito bites. The diagnostics cover many techniques like night blood smears, PCR, detection of antigens, etc.

The screening of lymphatic filariasis helps in identifying the target disease in the population at risk and also in the implementation of prevention strategies (Pastor et al. 2019). It can be done by conducting surveys, vector control measures, etc. But it's also important to consider effective drug development, knowing the health technologies through gadgets, and innovative ways combined with traditional ones. In recent times the most hyped and capable tool CRISPR-Cas9 as genome editing to generate new possibilities in the site of treating lymphatic filariasis (Kwarteng et al. 2021). This technology destroys the life cycle of filarial worms. Through identifying the target genes of both culprit and victims i.e. mosquito and human respectively. The approach is to create resistance for parasitic worms to become mature, reproduce, and host in humans. However, there is no such record that an approved vaccine is developed for this disease. But the trials are being made to introduce a vaccine specifically for Wuchereria bancrofti. The complicated life cycle of filarial parasites hinders to inducement of any immune response to fight against disease. However, the trials made particular targets to identify the antigens that as a result be used for developing vaccines (Das, Chakraborty et al. 2023)

2. DIAGNOSIS AND SCREENING

Lymphatic filariasis is a parasitic disease caused by roundworms that is transmitted to humans through the bite of an infected mosquito. The following methods are commonly used to diagnose and study this disease.

2.1. PHYSICAL EXAMINATION

Doctors may examine patients for physical symptoms, such as swollen limbs (lymphedema) or swollen scrotum (edema), which are characteristic signs of lymphatic filariasis (Mahalingashetti, Subramanian et al. 2014).

2.2. LABORATORY TESTS

Microscopic examination of blood smears: A blood sample is examined under a microscope to check for the presence of microfilariae, the larval stages of heartworms, in the blood. Serological tests: These tests detect antibodies to roundworms in the blood, indicating infection. These are particularly useful for detecting early or asymptomatic cases (Organization 2021).

2.3. MOLECULAR TECHNOLOGY (PCR)

The polymerase chain reaction (PCR) test can detect the presence of filarial DNA in blood samples, providing a highly sensitive and specific diagnostic method (Rao, Atkinson et al. 2006).

2.4. SCREENING PROGRAMS AND STRATEGIES

Screening programs are in place in endemic areas to combat lymphatic filariasis. This may involve high-dose antifilarial drugs (MDA) across at-risk populations, even in asymptomatic cases. This helps reduce the number of parasites in the community and stop transmission (Bockarie, Taylor et al. 2009).

2.5. TREATMENT AND MANAGEMENT

In addition, other preventive measures include vector control (mosquito control) and health education to raise awareness about the disease, its transmission and how to prevent it.
Early detection and prompt treatment are critical to prevent serious complications and reduce the prevalence of lymphatic filariasis. A regular inspection program is essential to control and ultimately eradicate the disease in affected areas.
Lymphatic filariasis is a parasitic infection transmitted by mosquito bites. Let's look at treatment and management options.

2.6. DRUG THERAPY

2.6.1. ANTIFILARIAL DRUGS

Diethylcarbamazine, ivermectin, and albendazole are commonly used to treat infections. Diethylcarbamazine helps kill adult worms, while ivermectin and albendazole target larvae. These drugs are usually given in combination (Shenoy, Suma et al. 2009).

2.7. DRUG COMBINATIONS AND TREATMENT PLANS

The specific drug combination and treatment regimen will depend on the severity of the infection and the recommendations of your health care professional. A combination of antifilarial drugs is usually prescribed to maximize effectiveness (Olsen 2007).

2.8. SURGICAL INTERVENTION FOR ADVANCED DISEASE

Advanced lymphatic filariasis may require surgical intervention to reduce complications. Surgical intervention is aimed at improving lymph flow and reducing swelling. These procedures are usually considered for severe lymphedema or elephantiasis (2019).



Fig. 1: Prevention and control of Lymphatic Filariasis

2.9. TREATMENT OF ASSOCIATED COMPLICATIONS (SUCH AS SECONDARY BACTERIAL INFECTIONS)

Secondary bacterial infections can occur in skin areas affected by lymphedema. Proper wound care and antibiotic treatment are essential to manage these complications and prevent further health problems. It is important to note that prevention is essential to control lymphatic filariasis. These include mosquito control measures and mass drug administration to vulnerable populations in endemic areas. If you suspect that you or someone you know has lymphocytic filariasis, it is essential to see a doctor for proper diagnosis and treatment (Boccardo, Campisi et al. 2012).

3. PREVENTION AND CONTROL

Prevention and control of lymphatic filariasis are essential to reduce its transmission, prevent disability and suffering, and eventually eliminate the disease. Several strategies are used to achieve these goals as shown in Fig. 1:

3.1. MASS DRUG ADMINISTRATION (MDA)

The most effective approach to control lymphatic filariasis is through the distribution of preventive medications. The World Health Organization (WHO) recommends using a combination of two drugs, usually ivermectin and albendazole or diethylcarbamazine (DEC) and albendazole, to kill the microfilariae (larval stage) of the filarial worms. MDA involves administering these drugs once or twice a year to all eligible individuals in endemic areas, even if they show no symptoms. Treating the entire at-risk population helps reduce the number of microfilariae circulating in the community and interrupts the transmission cycle (Talbot, Viall et al. 2008).



Fig. 2: Prevention and Control of Vector.

3.2. VECTOR CONTROL

Since lymphatic filariasis is transmitted by infected mosquitoes, controlling the mosquito population is crucial. This can be accomplished by taking steps including employing bed nets sprayed with pesticide, indoor residual spraying, and managing the environment to eliminate mosquito breeding grounds as show in Fig. 2 (Bockarie, Taylor et al. 2009).

3.3. PREVENTIVE HEALTH STRATEGIES AND COMMUNITY ENGAGEMENT

To promote community involvement in control efforts, it is essential to raise awareness about the disease, its transmission, and prevention methods. Education campaigns help communities understand the importance of MDA and vector control, as well as the benefits of personal protective measures like using bed nets and wearing long-sleeved clothing (Agrawal and Sashindran 2006).

3.4. MORBIDITY MANAGEMENT AND DISABILITY PREVENTION (MMDP)

For individuals already affected by lymphatic filariasis and suffering from chronic symptoms like elephantiasis or hydrocele (swelling of the scrotum), it is essential to provide appropriate care and support. This includes managing acute attacks, preventing secondary infections, promoting hygiene, and providing physical therapy and rehabilitation services to improve the quality of life (Chandrasena, Premaratna et al. 2018).

3.5. SURVEILLANCE AND MONITORING

Regular monitoring and surveillance systems are necessary to assess the effectiveness of control programs, track progress, and identify areas that still require intervention.

3.6. STRENGTHENING HEALTH SYSTEMS

Building and strengthening healthcare infrastructure in endemic areas helps ensure the efficient delivery of prevention and control measures. It involves training healthcare workers, improving diagnostic capabilities, and ensuring the availability of essential drugs and supplies (Zulu, Maritim et al. 2022).

3.7. COLLABORATION AND PARTNERSHIPS

A multi-sectorial strategy involving governments, international organizations, non-governmental organizations (NGOs), and affected communities is necessary to combat lymphatic filariasis. Collaborative efforts enhance the effectiveness of control programs and resource mobilization (ASSEMBLY and SANTÉ 1997).

It Is important to note that the success of prevention and control efforts depends on sustained commitment and funding from governments and international partners. Combined efforts can result in the eradication of lymphatic filariasis as a public health issue and decrease the suffering of the millions of people infested by this crippling illness (Organization 2010).

4. LYMPHATIC FILARIASIS: SOCIOECONOMIC AND PSYCHOSOCIAL IMPACTS

The parasitic worms that cause lymphatic filariasis are spread through mosquito bites from affected individuals. It is a neglected tropical disease. As a result of the parasites' primary impact on the lymphatic system, body parts like the limbs and genitalia expand. This chronic and debilitating condition has significant socioeconomic and psychosocial impacts on affected individuals and communities (Wynd, Melrose et al. 2007).

4.1. ECONOMIC BURDEN ON INDIVIDUALS AND COMMUNITIES

4.1.1. MEDICAL COSTS

Lymphatic filariasis requires long-term management, including medication, regular check-ups, and possible surgeries. These medical expenses can impose a substantial financial burden on both individuals and healthcare systems (Gyapong, Gyapong et al. 1996).

4.2. REDUCED WORK PRODUCTIVITY

The physical impairments caused by the disease can hinder an individual's ability to work. Swollen limbs or genitalia may prevent people from engaging in certain occupations, leading to reduced productivity and income.

4.3. STIGMA AND DISCRIMINATION

The visible disfigurement and disabilities resulting from lymphatic filariasis can lead to stigmatization and discrimination in employment and social settings. This can further hinder affected individuals from finding or maintaining jobs, exacerbating their economic struggles (Ramaiah, Das et al. 2000).

4.4. OPPORTUNITY COST

When individuals are unable to work or participate fully in daily activities, they miss out on potential economic opportunities, further perpetuating poverty cycles.

4.5. REDUCED COMMUNITY PRODUCTIVITY

If the disease affects a significant portion of a community, the overall productivity of that community may decline due to the cumulative effects of lost workdays and diminished labor capacity.

4.6. SOCIAL STIGMA AND DISCRIMINATION

4.6.1. APPEARANCE-BASED STIGMA

Swollen limbs, genitalia, or other visible manifestations of the disease can lead to social isolation and discrimination. Affected individuals may be subjected to ridicule, negative attitudes, and avoidance by others (Abdulmalik, Nwefoh et al. 2018).

4.7. MARITAL AND SOCIAL EXCLUSION

In some cultures, individuals with lymphatic filariasis may face difficulties in finding a partner for marriage due to societal perceptions about the disease. This exclusion from social and family life can lead to feelings of loneliness and depression (Person, Bartholomew et al. 2009).

4.8. EDUCATIONAL DISRUPTION

Children affected by lymphatic filariasis might experience discrimination and teasing by their peers, which can lead to reduced school attendance and hinder their educational development.

4.9. COMMUNITY REJECTION

Entire families may face discrimination within their communities, affecting their social integration and overall well-being.

4.10. PSYCHOLOGICAL IMPACT ON AFFECTED INDIVIDUALS

4.10.1. MENTAL DISTRESS

Living with a chronic and stigmatized condition can lead to anxiety, depression, and feelings of hopelessness in affected individuals.(Ton, Mackenzie et al. 2015).

4.11. BODY IMAGE ISSUES

The physical disfigurements caused by the disease can negatively impact body image, leading to low self-esteem and self-confidence.

4.12. SOCIAL ANXIETY

Fear of rejection and social isolation can lead to increased social anxiety in individuals with lymphatic filariasis (Krishna Kumari, Harichandrakumar et al. 2005).

4.13. EMOTIONAL BURDEN

Coping with the long-term effects of the disease, including pain and physical limitations, can place an emotional burden on affected individuals and their families.
Overall, the socioeconomic and psychosocial impacts of lymphatic filariasis highlight the importance of comprehensive approaches to disease management. To improve the general wellbeing of impacted people and communities, these strategies should not only focus on medical therapies but also address social stigma, offer mental health assistance, and encourage economic development. The impact of this neglected tropical disease can be significantly reduced by public health initiatives that emphasize prevention, early detection, and treatment.

4.14. SUCCESS STORIES AND CHALLENGES IN DIFFERENT REGIONS

Positive progress has been done for the elimination and transmission control of Lymphatic filariasis and many different strategies like MDA, MMDP and vector control have played a big role for the disease control.

4.15. (INTIMATE'S STORY)

A local inhabitant of Orissa, India, Indurate (mother of seven and 58-year-old widow) thought that can never be out of this disease like all the other Lymphatic Filariasis patients and that will be forever self-isolated. She has been suffering by lymphedema (swelling) of the leg because of LF for nearly 25 years. Indurate was even reluctant to visit her girls, for dread they and their grandchildren would be terrified in response to her sickness.
LF is one of the world's most health draining diseases, with 120 million people already affected by it. Symptoms are painful which includes swelling of arms, legs, and breasts. Another effect of LF is that many individuals who suffer from LF are rejected by their communities.
Many NGOs along with Disease Control and Prevention (CDC) and India's Church's Auxiliary for Social Action (CASA) are working in collaboration to help the patients of Lymphatic Filariasis. CDC ran different campaigns which involve yearly distribution of medicine to groups at risk, to halt the spread of infection.
CASA workers have started programs in Intimate's village and are raising awareness on LF. Management of Lymphatic Filariasis includes exercise of the affected limbs and cleaning the affected regions with water and soap. These minimal measures help to stop severe attacks of LF.
Since workers helped Indurate learn new techniques, she is now much better without the severe Lymphatic Filariasis attacks and now living a normal life. "Because of [CASA] now I am able to lead a better life. Now my grandchildren come to me without any hesitation," Indurate reported ecstatically (Babu, Acharya et al. 2001).

5. GENOME EDITING AS CONTROL INSTRUMENT FOR LF

5.1. MECHANISM OF TREATMENT FOR LYMPHATIC FILARSIS BY GENOME EDITING

As of the last update in September 2021, there were no widely accepted genome editing-based cures for lymphatic filariasis. However, I can provide you with some insights into the concept of using genome editing for potential cures.
Genome editing techniques like CRISPR-Cas9 have revolutionized the field of genetics and offer potential opportunities for developing therapies against various diseases, including infectious diseases caused by parasites like *Wuchereria bancrofti*. crispr-cas9 works as follows as shown in Fig. 3.

5.2. IDENTIFYING TARGET GENES

Scientists first identify specific genes that are important for the survival or reproduction of the *Ucherella bancroft* parasite.

5.3. DESIGN OF THE CRISPR-CAS9 SYSTEM

Once the target gene is identified, the guide RNA (gRNA) is designed to be complementary to the specific gene sequence. This gRNA is a molecular guide directing the Cas9 enzyme to the exact spot in the parasite genome where the target gene resides.

5.4. DELIVERY OF CRISPR-CAS9 TO THE PARASITE

Next, the CRISPR-Cas9 system is delivered to the parasite, which can be a complex and difficult step. Various delivery methods can be considered, including the use of viral vectors, nanoparticles, or other delivery vehicles that can effectively deliver the CRISPR components to the parasite (Kwarteng, Sylverken et al. 2021).

5.5. EDITING THE PARASITE GENOME

Once inside the parasite, the CRISPR-Cas9 system recognizes target genes and induces cleavage of their DNA. The parasite's repair machinery may attempt to repair this damage, but often makes mistakes that cause genetic mutations that disrupt target gene function.

5.6. INACTIVATION OR DESTRUCTION OF THE PARASITE

With essential genes disrupted or modified, the parasite may become unable to survive or reproduce, effectively neutralizing its ability to cause lymphatic filariasis in the human host.

5.7. MONITORING AND VALIDATION

Extensive monitoring needed for CRISPR-Cas9 treatment efficacy and safety without side effects (Torres, Prince et al. 2022).

It is guided by small RNA sequence provides site for endonucleases. The CRISPR/Cas9 system is a simple endonuclease system consisting of Cas9, two RNA molecules, and the Cas9 protein. The system is guided to the target genomic locus by a short RNA sequence called crRNA. The second RNA, Trans activating crRNA or tracrRNA, pairs with the crRNA to create a lops-based RNA structure, directing Cas9 to the target locus with a PAM sequence. NHEJ or homology-directed repair are options for fixing the DSB.

CRISPR-Cas9 genome editing techniques for treating lymphatic filariasis remain in theoretical and experimental research, with challenges like efficient delivery, avoiding off-target effects, and ethical considerations requiring further development.

As of September 2021, information is accurate; updates may occur. Consult the latest scientific literature or a qualified medical professional for the most up-to-date information.

5.8. REVOLUTIONIZING LYMPHATIC FILARIASIS CONTROL: THE TRANSFORMATIVE APPLICATIONS OF GENOME EDITING

Elephantiasis, or lymphatic filariasis, is a parasitic illness brought on by nematode worms that are spread by mosquito bites. It causes swelling in legs and genital areas, potentially causing permanent disability. The application of genome editing in relevance to lymphatic filariasis can be explored in several ways:



Fig. 3: Gene edited by CRISPR Cas9 system.

5.9. GENE EDITING OF THE PARASITE

Gene editing of the filarial parasite involves targeting essential genes, preventing its survival or propagation within the human host. Researchers can use CRISPR-Cas9 or other tools to disrupt infection or reduce virulence.

5.10. GENE EDITING OF THE MOSQUITO VECTOR

Genome editing can modify mosquito genes responsible for transmitting filarial worms, potentially reducing or eliminating their ability to carry and transmit the disease to humans (Severson and Behura 2012).

5.11. HOST GENETIC MODIFICATION

Genome editing can modify genes in the human host to confer resistance to lymphatic filariasis, enhancing immune response and reducing disease impact.

Genome editing holds potential, but challenges and ethical considerations must be addressed for safe, responsible deployment in real-world scenarios (Nutman 2013).

5.12. OFF-TARGET EFFECTS

Genome editing technologies must be specific to prevent unintended changes and potential consequences (Krotneva, Coffeng et al. 2015).

5.13. DELIVERY

Effective delivery of the gene-editing tools to the target cells or organisms, whether parasites, mosquitoes, or human hosts, remains a challenge.

5.14. REGULATORY AND ETHICAL CONSIDERATIONS

Genome editing in disease control raises ethical concerns, including ecological consequences and informed consent for human interventions (Kouassi, Barry et al. 2018).

5.15. SAFETY AND EFFICACY

Preclinical research and clinical trials are crucial for genome editing safety and efficacy.
Genome editing research advances rapidly, so consult recent sources for latest developments in combating lymphatic filariasis and other diseases.

5.16. ADVANCING BIOINFORMATICS AND BIOTECHNOLOGY IN THE BATTLE AGAINST LYMPHATIC FILARIASIS: A PIONEERING APPROACH

An infection with nematode worms known as lymphatic filariasis, often called elephantiasis, is spread by mosquito bites. It is a major public health issue in tropical and subtropical regions. Bioinformatics and biotechnology are essential for understanding, developing diagnostic tools, and developing control and treatment strategies.

5.17. GENOME SEQUENCING

Bioinformatics analyzes genomic data using computational tools. Sequencing filarial parasite genomes, like *Wuchereria bancrofti* and *Brugia malayi*, offers insights into their biology, aiding researchers in drug targets identification and understanding resistance mechanisms (Williams, Lizotte-Waniewski et al. 2000).

5.18. IDENTIFICATION OF DRUG TARGETS

Analyzing filarial parasite genomic and proteomic data enables bioinformaticians to identify essential genes and proteins for worm survival and reproduction. These targets can be used for drug development or repurposing, effectively treating the disease.

5.19. VACCINE DEVELOPMENT

Bioinformatics is crucial in identifying and designing potential vaccines against lymphatic filariasis. By analyzing parasite genomes and their interactions with the host immune system, researchers can identify antigens that may elicit a protective immune response. This information aids in rational vaccine design and preclinical and clinical trials (Kalyanasundaram, Khatri et al. 2020).

5.20. TRANSCRIPTOMICS AND PROTEOMICS

Transcriptomics and proteomics aid researchers in understanding filarial parasite gene expression and protein profiles, identifying differentially expressed genes and revealing mechanisms underlying parasite development and transmission.

5.21. DIAGNOSTICS

Bioinformatics can enhance diagnostic tools for lymphatic filariasis by analyzing filarial worm genetic material, enabling sensitive PCR-based assays to detect parasite presence in human samples. These molecular diagnostic methods are more accurate than traditional methods, aiding early disease detection and monitoring (Misra-Bhattacharya and Shahab 2018).

5.22. POPULATION GENETICS

Bioinformatics tools analyze filarial parasite population genetic data, providing insights into spread and distribution, tracking transmission patterns, and identifying intervention areas.

5.23. DRUG RESISTANCE MONITORING

Biotechnological tools monitor drug resistance in filarial parasites by analyzing genomic data, revealing genetic mechanisms, and adjusting treatment strategies accordingly (Sharma, Vadlamudi et al. 2013).
Integrating bioinformatics and biotechnology is crucial for understanding lymphatic filariasis, developing treatments, and eradicating the disease. This facilitates data-driven research and provides powerful tools for effective global health challenges.

5.24. RESULTS AND DISCUSSION LYMPHATIC FILARIASIS

Lymphatic filariasis, also known as elephantiasis, is a parasitic disease caused by filarial worms, Wuchereria bancrofti and Brugia malayi and timori. These worms primarily affect the lymphatic system and are found in Africa, Southeast Asia, the Indian subcontinent, the Pacific Islands, and some parts of the Americas.

5.25. TRANSMISSION

Lymphatic filariasis is transmitted through infected mosquito bites, where microfilariae enter the bloodstream, migrate to lymphatic vessels, and grow into adult worms, which can live for years in the human host.

5.26. LIFECYCLE

Filarial worms have a life cycle consisting of two stages: the human host and the mosquito vector. In the human host, worms' mate, releasing microfilariae into the bloodstream. These microfilariae can be picked up by mosquitoes during a blood meal. Once inside, they mature into infective larvae, which can be transmitted to another human.

REFERENCES

(2019). "Surgical Treatment of Advanced Lymphatic Filariasis of Lower Extremity Combining Vascularized Lymph Node Transfer and Excisional Procedures." Lymphatic Research and Biology **17**(6): 637-646.

Abdulmalik J et al., 2018. "Emotional difficulties and experiences of stigma among persons with lymphatic filariasis in Plateau State, Nigeria." Health and human rights 20(1): 27.

Abdulmalik, J., et al. (2018). "Emotional difficulties and experiences of stigma among persons with lymphatic filariasis in Plateau State, Nigeria." Health and human rights **20**(1): 27.

Agrawal V and Sashindran V, 2006. "Lymphatic filariasis in India: problems, challenges and new initiatives." Medical Journal Armed Forces India 62(4): 359-362.

Agrawal, V. and V. Sashindran (2006). "Lymphatic filariasis in India: problems, challenges and new initiatives." Medical Journal Armed Forces India **62**(4): 359-362.

ASSEMBLY F and SANTÉ L, 1997. Elimination of lymphatic filariasis as a public health problem, GENEVA, SWITZERLAND: WORD HEALTH ASSEMBLY.

ASSEMBLY, F. and L. SANTÉ (1997). Elimination of lymphatic filariasis as a public health problem, GENEVA, SWITZERLAND: WORD HEALTH ASSEMBLY.

Babu BV et al., 2001. "Lymphatic filariasis in Khurda district of Orissa, India: an epidemiological study." Southeast Asian J Trop Med Public Health 32(2): 240-243.

Babu, B. V., et al. (2001). "Lymphatic filariasis in Khurda district of Orissa, India: an epidemiological study." Southeast Asian J Trop Med Public Health **32**(2): 240-243.

Boccardo F et al., 2012. "Lymphatic complications in surgery: possibility of prevention and therapeutic options." Updates in surgery 64: 211-216.

Boccardo, F., et al. (2012). "Lymphatic complications in surgery: possibility of prevention and therapeutic options." Updates in surgery **64**: 211-216.

Bockarie MJ et al., 2009. "Current practices in the management of lymphatic filariasis." Expert Review of Anti-infective Therapy 7(5): 595-605.

Bockarie, M. J., et al. (2009). "Current practices in the management of lymphatic filariasis." Expert Review of Anti-infective Therapy **7**(5): 595-605.

Chilgar RM et al., 2019. "Surgical Treatment of Advanced Lymphatic Filariasis of Lower Extremity Combining Vascularized Lymph Node Transfer and Excisional Procedures." Lymphatic Research and Biology 17(6): 637-646.

Chandrasena Net al., 2018. "Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects." PLOS Neglected Tropical Diseases 12(5): e0006472.

Chandrasena, N., et al. (2018). "Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects." PLOS Neglected Tropical Diseases **12**(5): e0006472.

Das, N. C., et al. (2023). "Programmed cell death pathways as targets for developing antifilarial drugs: Lessons from the recent findings." Journal of Cellular and Molecular Medicine **27**(19): 2819-2840.

Gyapong et al., 1996. "The economic burden of lymphatic filariasis in northern Ghana." Annals of Tropical Medicine & Parasitology 90(1): 39-48.

Gyapong, J. O., et al. (1996). "The economic burden of lymphatic filariasis in northern Ghana." Annals of Tropical Medicine & Parasitology **90**(1): 39-48.

Kalyanasundaram et al., 2020. "Advances in vaccine development for human lymphatic filariasis." Trends in parasitology 36(2): 195-205.

Kalyanasundaram, R., et al. (2020). "Advances in vaccine development for human lymphatic filariasis." Trends in parasitology **36**(2): 195-205.

Kouassi et al., 2018. "Perceptions, knowledge, attitudes and practices for the prevention and control of lymphatic filariasis in Conakry, Republic of Guinea." Acta tropica 179: 109-116.

Kouassi, B. L., et al. (2018). "Perceptions, knowledge, attitudes and practices for the prevention and control of lymphatic filariasis in Conakry, Republic of Guinea." Acta tropica **179**: 109-116.

Krishna Kumari et al., 2005. "Physical and psychosocial burden due to lymphatic filariasis as perceived by patients and medical experts." Tropical Medicine & International Health 10(6): 567-573.

Krishna Kumari, A., et al. (2005). "Physical and psychosocial burden due to lymphatic filariasis as perceived by patients and medical experts." Tropical Medicine & International Health **10**(6): 567-573.

Krotneva et al., 2015. "African program for onchocerciasis control 1995–2010: impact of annual ivermectin mass treatment on off-target infectious diseases." PLoS neglected tropical diseases 9(9): e0004051.

Krotneva, S. P., et al. (2015). "African program for onchocerciasis control 1995–2010: impact of annual ivermectin mass treatment on off-target infectious diseases." PLoS neglected tropical diseases **9**(9): e0004051.

Kwarteng et al., 2021. "Genome editing as control tool for filarial infections." Biomedicine & Pharmacotherapy 137: 111292.

Kwarteng, A., et al. (2021). "Genome editing as control tool for filarial infections." Biomedicine & Pharmacotherapy **137**: 111292.

Lourens GB and Ferrell DK, 2019. Lymphatic filariasis. Nursing Clinics. 54(2): 181-92.

Mahalingashetti et al., 2014. "Lymphatic filariasis: A view at pathological diversity." Trop Parasitol 4(2): 128-132.

Mahalingashetti, P. B., et al. (2014). "Lymphatic filariasis: A view at pathological diversity." Trop Parasitol **4**(2): 128-132.

Misra-Bhattacharya et al., 2018. "Progress in the treatment and control of lymphatic filariasis." Lymphatic Filariasis: Epidemiology, Treatment and Prevention-The Indian Perspective: 47-58.

Misra-Bhattacharya, S. and M. Shahab (2018). "Progress in the treatment and control of lymphatic filariasis." Lymphatic Filariasis: Epidemiology, Treatment and Prevention-The Indian Perspective: 47-58.

Nutman and Thomas B, 2013. "Insights into the pathogenesis of disease in human lymphatic filariasis." Lymphatic research and biology 11(3): 144-148.

Nutman, T. B. (2013). "Insights into the pathogenesis of disease in human lymphatic filariasis." Lymphatic research and biology **11**(3): 144-148.

Olsen and Annete, 2007. "Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis." Transactions of the Royal Society of Tropical Medicine and Hygiene 101(8): 747-758.

Olsen, A. (2007). "Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis." Transactions of the Royal Society of Tropical Medicine and Hygiene **101**(8): 747-758.

Organization, W. H. (2010). Progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis, World Health Organization.

Organization, W. H. (2021). "Diagnostic test for surveillance of lymphatic filariasis: target product profile."

Pastor AF et al., 2021. Recombinant antigens used as diagnostic tools for lymphatic filariasis. Parasites & Vectors 14(1): 1-4.

Person et al., 2009. "Health-related stigma among women with lymphatic filariasis from the Dominican Republic and Ghana." Social Science & Medicine 68(1): 30-38.

Person, B., et al. (2009). "Health-related stigma among women with lymphatic filariasis from the Dominican Republic and Ghana." Social Science & Medicine **68**(1): 30-38.

Ramaiah et al., 2000. "The economic burden of lymphatic filariasis in India." Parasitology Today 16(6): 251-253.

Ramaiah, K. D., et al. (2000). "The economic burden of lymphatic filariasis in India." Parasitology Today **16**(6): 251-253.

Rao et al., 2006. "A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes." Am J Trop Med Hyg 74(5): 826-832.

Rao, R. U., et al. (2006). "A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes." Am J Trop Med Hyg **74**(5): 826-832.

Severson et al., 2012. "Mosquito genomics: progress and challenges." Annual review of entomology 57: 143-166.

Severson, D. W. and S. K. Behura (2012). "Mosquito genomics: progress and challenges." Annual review of entomology **57**: 143-166.

Sharma, O. P., et al. (2013). "Drug targets for lymphatic filariasis: a bioinformatics approach." Journal of vector borne diseases **50**(3): 155.

Shenoy et al., 2009. "Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection." Annals of Tropical Medicine & Parasitology 103(3): 235-247.

Shenoy, R. K., et al. (2009). "Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection." Annals of Tropical Medicine & Parasitology **103**(3): 235-247.

Talbot et al., 2008. "Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic filariasis in Leogane, Haiti." The American journal of tropical medicine and hygiene 78(2): 283-288.

Talbot, J. T., et al. (2008). "Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic filariasis in Leogane, Haiti." The American journal of tropical medicine and hygiene **78**(2): 283-288.

Ton et al., 2015. "The burden of mental health in lymphatic filariasis." Infectious diseases of poverty 4(1): 1-8.

Ton, T. G., et al. (2015). "The burden of mental health in lymphatic filariasis." Infectious diseases of poverty **4**(1): 1-8.

Torres et al., 2022. "Optimized In Vitro CRISPR/Cas9 Gene Editing Tool in the West Nile Virus Mosquito Vector, Culex quinquefasciatus." Insects 13(9): 856.

Torres, T. Z. B., et al. (2022). "Optimized In Vitro CRISPR/Cas9 Gene Editing Tool in the West Nile Virus Mosquito Vector, Culex quinquefasciatus." Insects **13**(9): 856.

Williams et al., 2000. "The filarial genome project: analysis of the nuclear, mitochondrial and endosymbiont genomes of Brugia malayi." International journal for parasitology 30(4): 411-419.

Williams, S., et al. (2000). "The filarial genome project: analysis of the nuclear, mitochondrial and endosymbiont genomes of Brugia malayi." International journal for parasitology **30**(4): 411-419.

World Health Organization, 2010. Progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis, World Health Organization.

World Health Organization, 2021. "Diagnostic test for surveillance of lymphatic filariasis: target product profile."

Wynd et al., 2007. "Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature." Bulletin of the World Health Organization 85: 493-498.

Wynd, S., et al. (2007). "Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature." Bulletin of the World Health Organization **85**: 493-498.

Zulu et al., 2022. "Unlocking trust in community health systems: lessons from the lymphatic filariasis morbidity management and disability prevention pilot project in Luangwa District, Zambia." International Journal of Health Policy and Management 11(1): 80.

Zulu, J. M., et al. (2022). "Unlocking trust in community health systems: lessons from the lymphatic filariasis morbidity management and disability prevention pilot project in Luangwa District, Zambia." International Journal of Health Policy and Management **11**(1): 80